Efficacy of once daily human GLP-1 analogue, Liraglutide on dietary lifestyle and treatment satisfaction in type 2 diabetic patients.
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000010614
- Lead Sponsor
- Osaka Saiseikai Noe Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Contraindication of Liraglutide Comorbidity of endocrine disease except diabetes. Existence of severe diabetic complication like diabetic nephropathy severer than grade III by criteria of Japan Diabetes Society and diabetic retinopathy severer than by criteria of Japan Diabetes Society.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does Liraglutide's GLP-1 receptor agonism influence dietary behavior and glycemic control in type 2 diabetes?
What is the comparative effectiveness of once-daily Liraglutide versus metformin on dietary adherence and treatment satisfaction in type 2 diabetes?
Which biomarkers predict response to Liraglutide in terms of treatment satisfaction and metabolic outcomes for type 2 diabetes patients?
What are the known adverse events and management strategies for Liraglutide in type 2 diabetes patients, based on JPRN-UMIN000010614?
How do combination therapies involving Liraglutide and other GLP-1 analogues improve dietary lifestyle and treatment satisfaction in type 2 diabetes?